Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Primary Sjögren's Syndrome
NCT06862284Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of upadacitinib in primary Sjögren's syndrome (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sjögren's Tool for Assessing Response at 24 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT06862284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862284.